Page last updated: 2024-12-07

2,2'-azobis(2,4-dimethylvaleronitrile)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,2'-azobis(2,4-dimethylvaleronitrile): free radical initiator in liposome systems [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91537
SCHEMBL ID14897
MeSH IDM0156858

Synonyms (50)

Synonym
LS-14343
einecs 224-583-8
4419-11-8
2,2'-azobis(2,4-dimethylvaleronitrile)
FT-0651305
2-[(2-cyano-4-methylpentan-2-yl)diazenyl]-2,4-dimethylpentanenitrile
advn
amvn
A0680
2,2'-azobis(2,4-dimethylpentanenitrile)
unii-02830lwz4x
pentanenitrile, 2,2'-(1,2-diazenediyl)bis(2,4-dimethyl-
pentanenitrile, 2,2'-azobis(2,4-dimethyl-
02830lwz4x ,
2,2'-azobis(2,4-dimethyl)valeronitrile
AKOS015915240
2,2'-azobis[2,4-dimethylpentanenitrile]
SCHEMBL14897
2,2'-azobis-(2,4'-dimethylvaleronitrile)
2,2'-azobis-(2,4-dimethylvaleronitrile)
2,2'-azobis(2,4-dimethyl valeronitrile)
2,2'-azobis(2,4-dimethylpentanonitrile)
WYGWHHGCAGTUCH-UHFFFAOYSA-N
2,2'-azobis (2,4-dimethylvaleronitrile)
2,2'-azobis (2,4-dimethylpentanenitrile)
2,2'-azobis(2,4'-dimethylvaleronitrile)
2,2' azobis (2,4-dimethylpentanenitrile)
2,2'-azobis(2,4-dimethylvaleronitile)
abdv
2,2'azobis(2,4-dimethylpentanenitrile)
azobis(2,4-dimethylvaleronitrile)
2,2'-(diazene-1,2-diyl)bis(2,4-dimethylpentanenitrile)
1547296-70-7
valeronitrile, 2,2'-azobis(2,4-dimethyl-
pentanenitrile, 2,2'-(1e)-1,2-diazenediylbis(2,4-dimethyl-
J-506776
2,2'-azobis(2,4-dimethyl)-valeronitrile
(e)-2,2'-(diazene-1,2-diyl)bis(2,4-dimethylpentanenitrile)
2,2'-azobis[2,4-dimethylvaleronitrile]
DTXSID3044675
2,2'-(e)-diazenediylbis(2,4-dimethylpentanenitrile)
DTXSID90859867
2,2-azobis(2,4-dimethylvaleronitrile)
Q27231503
2-[(e)-2-(1-cyano-1,3-dimethylbutyl)diazen-1-yl]-2,4-dimethylpentanenitrile
EN300-24754918
2-[(1e)-2-(1-cyano-1,3-dimethylbutyl)diazen-1-yl]-2,4-dimethylpentanenitrile
EN300-16049566
2-[2-(1-cyano-1,3-dimethylbutyl)diazen-1-yl]-2,4-dimethylpentanenitrile
Z1898820780

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The lack of toxicity in these specimens suggests that residual contents of inhibitor and initiator are too low to cause toxic effects on choroidal fibroblasts."( Cytotoxic effects of residual chemicals from polymeric biomaterials for artificial soft intraocular lenses.
Barrett, GD; Chirila, TV; Constable, IJ; Thompson, DE; Walker, LN, 1991
)
0.28
" The results suggest that the changes in cellular milieu caused by bcl-2 gene transfection protect PC12 cells from the toxic effects of glutamate in a manner consistent with prevention of protein sulfhydryl oxidation."( Glutamate-induced cytotoxicity in PC12 pheochromocytoma cells: role of oxidation of phospholipids, glutathione and protein sulfhydryls revealed by bcl-2 transfection.
Balachandran, R; Day, BW; Kagan, VE; Quinn, PJ; Schor, NF; Tyurin, VA; Tyurina, YY, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (3.19)18.7374
1990's58 (61.70)18.2507
2000's27 (28.72)29.6817
2010's5 (5.32)24.3611
2020's1 (1.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.50 (24.57)
Research Supply Index4.61 (2.92)
Research Growth Index6.01 (4.65)
Search Engine Demand Index38.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other99 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]